Levodopa (L-DOPA) is an endogenous precursor to dopamine, norepinephrine, and epinephrine; it can also be found in bean plants such as species of Mucuna. L-DOPA increases brain dopamine concentrations and is clinically used to treat symptoms of Parkinson’s disease. Peripheral increases in dopamine cause many side effects, including dyskinesias, hypotension, and nausea.
| Cas No. | 59-92-7 |
|---|---|
| Purity | ≥98% |
| Formula | C9H11NO4 |
| Formula Wt. | 197.19 |
| Chemical Name | 3-Hydroxy-L-tyrosine |
| IUPAC Name | (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid |
| Synonym | Bendopa, Dopaflex, Dopaidan, Doparl, Dopaston, Eldopatec, L-DOPA, Maipedopa, Parda, Veldopa |
| Melting Point | 276-278°C (dec.) |
| Solubility | Soluble in water, dil HCl, and formic acid.Practically insoluble in ethanol, benzene, chloroform and ethyl acetate. |
| Appearance | A white or slightly cream crystalline powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Pahwa R, Lyons KE. Treatment of early Parkinson's disease. Curr Opin Neurol. 2014 Jun 19. [Epub ahead of print]. PMID: 24950010.
Pd Med Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014 Jun 10. [Epub ahead of print]. PMID: 24928805.
